Funder
National Institute of Mental Health
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Social Psychology
Reference16 articles.
1. US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. FDA News Release. 2012.
2. Murchu EO, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, Ryan M. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12(5): e048478.
3. Centers for Disease Control and Prevention. Monitoring select national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020. HIV Surveill Suppl Rep. 2021;27(3).
4. Zhu W, Huang YA, Kourtis AP, Hoover KW. Trends in the number and characteristics of HIV pre-exposure prophylaxis providers in the United States, 2014–2019. J Acquir Immune Defic Syndr. 2021;88(3):282–9.
5. Calabrese SK, Rao S, Eldahan AI, Tekeste M, Modrakovic D, Dangaran D, et al. "Let’s be a person to person and have a genuine conversation”: comparing perspectives on PrEP and sexual health communication between Black sexual minority men and healthcare providers. Arch Sex Behav. 2022;51(5):2583–601.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献